THE MOST INNOVATIVE SINGLE-USE ENDOSCOPY COMPANY - J.P. Morgan Healthcare Conference 14th of January 2021 - Ambu
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
THE MOST INNOVATIVE
SINGLE-USE
ENDOSCOPY COMPANY
J.P. Morgan Healthcare Conference
14th of January 2021
The world’s most Market opportunity and strategy
innovative single-use 2019/20 performance
endoscopy player Outlook
Disclaimer
Forward-looking statements, especially such relating to future sales and operating profit, are subject to risks and uncertainties. Various factors, many of which are outside Ambu’s control, may cause the actual development of
the company to differ materially from the expectations contained in this presentation. Factors that might affect such expectations include, among others, changes in healthcare, in the world economy and in exchange rates 2
Single-use endoscopy is one of the most attractive “new markets”
in MedTech
Drivers creating the single-use endoscopy market
DKK +17bn
Increased focus on contamination and
I
infection control from medical authorities
Rapid technology advancements
II strengthening single-use clinical
performance
Compelling economic offering and DKK ~3bn
III convenience making the transition from
reusable to single-use cost-effective
2020 2024
3
Ambu has transformed into the leading single-use endoscopy player
Competitive advantages
Visualization (single-use endoscopy)
World’s largest single-use endoscopy Patient Monitoring & Diagnostics
I player creating the market 10+ years ago Anaesthesia DKK 3.6bn
(~50% revenue CAGR in the last 4 years)
Modular innovation engine and high-scale 48%
II low-cost manufacturing driving richest DKK 2.1bn
pipeline in the market 16%
39% 22%
Dedicated commercial organization with
III focus on market creation and penetration 45% 30%
of single-use endoscopy products
2015/16 2019/20
4
At the core of Ambu is a unique R&D engine which combines…
Modularization expertise from automotive Rapid launch cadence from consumer electronics
Largest single-use endoscopy R&D infrastructure
- 3 large R&D centers (Denmark, Germany, Malaysia) and 10 exclusive technology partners
- Superior expertise in image resolution, mechanics and low-cost design 5
Ambu has embarked on a rapid expansion across all
endoscopy segments
Million of endoscopy procedures
(number of procedures in 2021/22)
94 ~100
Pulmonology (5m) Duodenoscopy (2m)
ENT (11m) Gastroscopy (20m)
Ureteroscopy (2m) Colonoscopy (50m)
Cystoscopy (6m) 50 50
20 20
22 2
2 2 6
14 6 6 2
11 11 11 11
3 3
3 3 5 +5
2016/17 2017/18 2018/19 2019/20 2020/21 2021/22
6
The world’s most Market opportunity and strategy
innovative single-use 2019/20 performance
endoscopy player Outlook
Disclaimer
Forward-looking statements, especially such relating to future sales and operating profit, are subject to risks and uncertainties. Various factors, many of which are outside Ambu’s control, may cause the actual development of
the company to differ materially from the expectations contained in this presentation. Factors that might affect such expectations include, among others, changes in healthcare, in the world economy and in exchange rates 7
COVID-19 pandemic is accelerating the development of the
single-use endoscopy market
▪ Pulmonology associations recommend
use of single-use bronchoscopy to
avoid cross contamination during the
COVID-19 pandemic
▪ Demand for Ambu aScope™ 4
Broncho has significantly increased
driving increased penetration and
expansion of customer base
▪ Hospitals are more open to single-use
endoscopy beyond pulmonology as
they look to perform elective
procedures safely
8
2019/20 was a record year for Ambu exceeding the 1m endoscopes sold
Organic Visualization growth of 81% in 2019/20 Endoscope units sold (‘000)
1,085
Europe 96%
Visualization organic revenue growth
618
North America 71% 560
Visualization organic revenue growth
364
200
Rest of World 55% 96
Visualization organic revenue growth
14 40
12/13 13/14 14/15 15/16 16/17 17/18 18/19 19/20
9Expansion into ENT and cystoscopy markets indicate potential
for widespread adoption
New growth engines Comparison of unit sales, aScope 3 vs. ENT vs. Cysto
▪ ENT and cystoscopy markets represent 17 million # of units sold in U.S. first 8 months
endoscopy procedures
aScope™ 3 Broncho
▪ Ambu’s value proposition – advanced technology and aScope™ 4 RhinoLaryngo (ENT)
affordable pricing – is attractive across geographies and aScope™ 4 Cysto
sites of care
▪ Major high-volume customers have embraced our
aScope™ ENT and aScope™ Cysto products
1 2 3 4 5 6 7 8
Months
10aScope™ Duodeno will be a major
growth engine for Ambu in 2020/21
▪ Single-use duodenoscopy is expected to be one
of the largest segments by revenue in 2025
▪ Our controlled market release confirms adequate
performance across ERCP procedures
▪ Our U.S. 550-patient clinical trial is expected to start
in January 2021
▪ Ambu U.S. GI commercial organization is 100%
in place driving over 550 product demonstrations
11The world’s most Market opportunity and strategy
innovative single-use 2019/20 performance
endoscopy player Outlook
Disclaimer
Forward-looking statements, especially such relating to future sales and operating profit, are subject to risks and uncertainties. Various factors, many of which are outside Ambu’s control, may cause the actual development of
the company to differ materially from the expectations contained in this presentation. Factors that might affect such expectations include, among others, changes in healthcare, in the world economy and in exchange rates 12We will enter the largest GI endoscopy segments this year
Product Launch
aView™ 2 Advance Commercially available
Monitors
aBox™ Console H2, 2020/21
aScope™ 4 Broncho
aScope BronchoSampler™
VivaSight™
Pulmonology aScope™ 5 HD Q4, 2020/21
aView™ 2 Advance
aScope™ 5 for smaller patients 2021/22
aScope™ 5 for selected procedures 2021/22
Video laryngoscope 2.0 2021/22
aScope™ 4 RL Intervention
ENT aScope™ 4 RL Slim
ENT High-Resolution 2021/22
aScope™ 4 Cysto
Urology Ureteroscope 2021/22
Cystoscope HD 2021/22
aScope™ Duodeno
Duodenoscopy (GI) aScope™ Duodeno 2 2021/22
Console
aBox™
Cholangioscope 2021/22
Colonoscopy (GI) aScope™ Colon H2, 2020/21
Gastroscopy (GI) aScope™ Gastro H2, 2020/21 13Ambu will emerge as the leading single-use player on the
back of its rich pipeline
8 8
new new 20 new products
products products
launches in the next
three years
4
new
3 products
new ~4x more products
2
products
new
products launches than in the
0
new previous three years
products
2017/18 2018/19 2019/20 2020/21 2021/22 2022/23
*product launches: new endoscopes and monitors 14We are building an ecosystem to support healthcare systems
transition to single-use endoscopy
Ambu’s ecosystem
▪ Most complete portfolio of
single-use endoscopes
▪ Monitors and consoles
leveraged across multiple
endoscopes
▪ Advanced diagnostic
capabilities
15Our 2020/21 guidance reflects Ambu’s strong momentum
17-20% 11-12% 1.3-1.4
organic EBIT million endoscope
growth margin units sold
(before special items)
Disclaimer
Forward-looking statements, especially such relating to future sales and operating profit, are subject to risks and uncertainties. Various factors, many of which are outside Ambu’s control, may cause the actual development of
the company to differ materially from the expectations contained in this presentation. Factors that might affect such expectations include, among others, changes in healthcare, in the world economy and in exchange rates 16Investor contact information
Share Information Financial calendar
Ambu A/S is listed on the stock exchange in 2021
Copenhagen under the symbol AMBU B
27 January Q1 2019/20
For further company information, please visit: 12 May Q2 2019/20
www.ambu.com
17 August Q3 2019/20
9 November Q4 2019/20
Investor Relations contacts
14 December Annual General Meeting 2020/21
Michael Højgaard
Executive Vice President, CFO For full list of Investor Relations events, please visit:
Tel.: +45 4030 4349
Email: miho@ambu.com www.ambu.com/calendar
Nicolai Thomsen
Director, Investor Relations
Tel.: +45 2620 8047
Email: nith@ambu.com
17Ambu – The single-use company
You can also read
